



JOURNAL OF SCIENTIFIC LETTERS
www.jslsci.com

**QUALITY BY DESIGN-BASED DEVELOPMENT AND
OPTIMIZATION OF ORAL TABLET MANUFACTURING
PROCESSES: A SYSTEMATIC APPROACH TO CRITICAL PROCESS
PARAMETERS AND PRODUCT QUALITY**

Singh Rahul Saroj

Research Scholar, Jayoti Vidyapeeth Women's University, Jaipur, Rajasthan

Dr. Avinash Shah

Research Supervisor, Jayoti Vidyapeeth Women's University, Jaipur, Rajasthan

ABSTRACT

Quality by Design (QbD) provides a systematic, science-based framework for developing pharmaceutical products with predefined quality characteristics and robust manufacturing processes. In oral tablet production, variability in material attributes and manufacturing operations can influence critical quality attributes such as assay, content uniformity, hardness, friability, disintegration, dissolution, and stability. This paper examines the application of QbD principles to the development and optimization of oral tablet manufacturing processes, with particular emphasis on critical material attributes, critical process parameters, risk assessment, design of experiments, design space, and control strategy. The approach begins with definition of the Quality Target Product Profile and identification of critical quality attributes, followed by systematic assessment of formulation and process variables. Process understanding can subsequently be strengthened through experimental studies and statistical modeling. ICH Q8 identifies QTPP, CQA, material attributes, process parameters, risk assessment, design space, and control strategy as central components of enhanced pharmaceutical development.

Keywords: Quality by Design, Oral Tablets, Critical Quality Attributes, Critical Process Parameters, Design of Experiments, Risk Assessment, Process Optimization, Pharmaceutical

Manufacturing

I. INTRODUCTION

Oral tablets remain among the most widely used pharmaceutical dosage forms because of their convenience, portability, stability, accurate dosing, and suitability for large-scale manufacturing. However, tablet production involves multiple interconnected operations, including dispensing, milling, blending, granulation where applicable, drying, lubrication, compression, coating, and packaging. Variability introduced at any stage can affect the final product. Differences in particle size, moisture content, powder flow, bulk density, compressibility, lubricant distribution, compression force, and machine operating conditions may influence tablet weight, hardness, friability, disintegration, dissolution, and content uniformity. Consequently, pharmaceutical development requires an understanding of how material characteristics and manufacturing parameters interact with final product quality.

Quality by Design provides a systematic alternative to relying primarily on end-product testing. ICH Q8(R2) describes pharmaceutical development around the Quality Target Product Profile (QTPP), identification of Critical Quality Attributes (CQAs), selection of appropriate formulation and manufacturing processes, and development of a control strategy. The enhanced QbD approach further emphasizes understanding relationships among material attributes, process parameters, and CQAs through prior knowledge, experimentation, and quality risk management. This approach is particularly relevant to oral tablets because their quality is determined by a combination of formulation composition and processing history rather than by a single manufacturing step.

A major strength of QbD is its emphasis on identifying and controlling sources of variability before they produce unacceptable product outcomes. Critical Process Parameters (CPPs) are process parameters whose variability can influence a CQA and therefore require appropriate monitoring or control. In tablet manufacturing, examples may include blending time and speed, granulation liquid addition rate, granulation endpoint, drying conditions, milling parameters, lubrication time, compression force, turret speed, and coating conditions, depending on the manufacturing process. Quality risk management helps prioritize these variables, while Design of Experiments (DoE) can be used to establish quantitative relationships between selected factors and responses. ICH materials specifically indicate that scientific rationale and quality risk management should support identification of CQAs and

CPPs.

The QbD approach also supports development of a scientifically justified control strategy and, where appropriate, a design space. Rather than treating manufacturing specifications as isolated limits, QbD seeks to understand how combinations of input materials and process conditions influence product quality. The resulting knowledge can support process validation, scale-up, technology transfer, continued process verification, and lifecycle improvement. FDA process-validation guidance similarly describes validation as a lifecycle activity involving process design, qualification, and continued process verification. Therefore, application of QbD to oral tablet manufacturing can provide a structured framework for achieving consistent product quality while improving process understanding and facilitating continual improvement.

II. QUALITY TARGET PRODUCT PROFILE, CRITICAL QUALITY ATTRIBUTES, AND RISK ASSESSMENT

The first stage of QbD-based tablet development is establishing a clear Quality Target Product Profile. The QTPP describes the intended characteristics of the finished dosage form and provides the foundation for subsequent identification of CQAs. For an immediate-release oral tablet, the QTPP may include dosage form, route of administration, strength, release characteristics, stability, appearance, packaging requirements, and other characteristics relevant to safety and efficacy. For modified-release tablets, the profile may additionally include the intended release mechanism and dissolution behavior. ICH Q8 specifically identifies the QTPP as the basis for pharmaceutical product design.

CQAs are measurable physical, chemical, biological, or microbiological characteristics that should remain within appropriate limits to ensure product quality. For conventional tablets, typical CQAs include identity, assay, content uniformity, tablet weight, hardness, friability, disintegration, dissolution, moisture content, and stability-related attributes. Not every measurable characteristic necessarily has the same level of criticality. QbD therefore emphasizes systematic assessment of the relationship between product attributes and patient requirements. CQAs should be selected using scientific knowledge and risk assessment rather than simply reproducing every routine specification as a critical attribute.

Once CQAs are identified, potential material attributes and process parameters that could affect them can be evaluated. Active pharmaceutical ingredient particle size, morphology,

polymorphic form, density, flow properties, moisture, and surface characteristics may affect blending, compression, dissolution, and content uniformity. Excipients can also contribute substantially to product performance. The type and concentration of binder, disintegrant, lubricant, diluent, glidant, and coating material can influence mechanical strength, disintegration, dissolution, and manufacturability. ICH Q8 recommends identifying material attributes and process parameters that may affect CQAs through prior knowledge, experimentation, and risk assessment.

Risk assessment provides a rational method for prioritizing variables. Tools such as Failure Mode and Effects Analysis, Ishikawa diagrams, risk-ranking matrices, and preliminary hazard analysis can be used during development. A high-risk parameter is not automatically a CPP; rather, its classification should be supported by evidence demonstrating its relationship with a CQA. For example, compression force may initially be considered a potentially high-risk parameter because it can influence hardness, porosity, disintegration, and dissolution. Experimental studies can subsequently determine whether the parameter actually has a significant effect within the proposed operating range.

Risk assessment should be iterative rather than performed only once. Initial assessments are generally based on prior knowledge and scientific understanding, whereas later assessments incorporate experimental evidence. ICH Q8/Q9/Q10 implementation materials emphasize that knowledge generated during development supports identification of CQAs and CPPs, development of the control strategy, lifecycle quality assurance, and evaluation of manufacturing changes. Thus, the risk profile of a tablet process can become more precise as development progresses.

The outcome of this stage is a scientifically justified development map connecting the QTPP to CQAs, material attributes, and process parameters. Such mapping prevents excessive experimentation by focusing development resources on variables most likely to influence product quality. It also establishes a logical foundation for subsequent DoE studies, process optimization, design-space development, and control-strategy establishment.

III. OPTIMIZATION OF CRITICAL PROCESS PARAMETERS USING EXPERIMENTAL DESIGN

After identification of potentially important variables, experimental studies are required to determine their actual influence on product quality. Design of Experiments is particularly

valuable because conventional one-factor-at-a-time experimentation may overlook interactions among variables. In tablet manufacturing, multiple process variables can act simultaneously. For example, compression force and turret speed may jointly influence tablet weight variation, hardness, tensile strength, and disintegration. DoE provides a structured way to evaluate main effects, interactions, curvature, and response behavior.

The selection of experimental factors should be based on prior knowledge and risk assessment. Depending on the manufacturing route, variables may include blending time, impeller speed, granulation liquid quantity, granulation endpoint, drying temperature, residual moisture, milling screen size, lubricant concentration, lubrication time, compression force, precompression force, turret speed, feeder speed, coating spray rate, inlet temperature, and atomization conditions. The specific parameters considered critical will depend on the formulation, equipment, manufacturing process, and intended product characteristics. This product-specific approach is consistent with the QbD principle that process understanding should be developed for the particular product and process.

Responses selected for DoE should represent relevant CQAs and important process outcomes. In tablet development, responses may include assay, content uniformity, hardness, friability, disintegration time, dissolution at selected time points, tablet weight variation, tensile strength, ejection force, and coating uniformity. Statistical models can then be used to estimate the relationship between process factors and responses. Multivariate models are especially useful where several responses must be optimized simultaneously.

Optimization should not simply identify a single "best" operating point. A robust process generally requires an operating region that provides acceptable quality despite normal process variability. ICH Q8 describes design space as the multidimensional combination and interaction of input variables and process parameters demonstrated to provide assurance of quality. Movement within an approved design space is not regarded in the same way as movement outside it, subject to applicable regulatory requirements. Thus, QbD shifts attention from isolated parameter values toward scientifically established operating ranges.

Model verification is an important part of the optimization process. Predicted outcomes should be compared with experimentally produced batches under selected conditions. Confirmation studies demonstrate whether the statistical model adequately represents the actual process. If experimental results do not agree with predictions, the formulation,

experimental design, model assumptions, or measurement system may need to be reassessed. This iterative process increases process understanding rather than treating statistical modeling as an end in itself.

The optimized process should ultimately provide acceptable product quality with sufficient robustness. The objective is not necessarily to maximize one response such as hardness or dissolution rate but to achieve a balanced set of quality requirements. For example, excessive compression may increase mechanical strength but potentially prolong disintegration, while excessive lubrication may reduce tablet strength and affect dissolution. A multidimensional optimization strategy can therefore identify conditions that simultaneously satisfy several CQAs. This is one of the major practical advantages of QbD-based development.

IV. CONTROL STRATEGY, PROCESS VALIDATION, AND CONTINUOUS IMPROVEMENT

A control strategy translates process knowledge into practical manufacturing controls. ICH Q10 describes a pharmaceutical quality system in which process performance and product quality monitoring are used to maintain a state of control and identify opportunities for continual improvement. The control strategy may include controls on materials and components, equipment operating conditions, in-process controls, finished-product specifications, and monitoring frequency. For oral tablets, this can involve control of raw-material characteristics, blend uniformity, granulation endpoint, moisture, tablet weight, compression parameters, and finished-product dissolution.

In-process controls are especially important because they provide information before a batch reaches final testing. Monitoring tablet weight and compression force, for example, can identify process drift during compression. Granulation moisture and endpoint measurements can provide information about downstream flow and compression behavior. For coating operations, process temperature, spray rate, and product-bed conditions can be monitored to reduce variability. The exact controls should be justified through product and process understanding rather than simply increasing the number of tests.

Process validation provides documented evidence that a manufacturing process can consistently produce product meeting predetermined quality requirements. FDA's process-validation framework emphasizes a lifecycle approach consisting broadly of process design, process qualification, and continued process verification. QbD-generated knowledge can

strengthen each stage by identifying critical sources of variability before commercial manufacturing and by establishing scientifically justified operating ranges.

Continued process verification is particularly relevant to QbD. ICH implementation materials describe continuous process verification as ongoing monitoring and evaluation of manufacturing performance and note that it can use in-line, on-line, or at-line monitoring. Statistical process-control methods, trend analysis, multivariate monitoring, and process capability analysis can help detect gradual shifts before they result in product failures. This creates a feedback mechanism between commercial manufacturing experience and process understanding.

Lifecycle management further extends the value of QbD. Manufacturing processes can change because of equipment replacement, scale-up, raw-material suppliers, facility changes, technology improvements, or regulatory requirements. ICH Q12 provides a framework for managing postapproval CMC changes and supports more predictable lifecycle management. A well-developed QbD knowledge base can make such changes easier to evaluate because relationships among materials, process parameters, and CQAs have already been characterized.

Finally, continual improvement should be incorporated into the pharmaceutical quality system. Deviations, complaints, out-of-specification results, stability data, process trends, and manufacturing experience can reveal opportunities to reduce variability. ICH Q10 emphasizes monitoring process performance and product quality, identifying sources of variation, and using accumulated knowledge to improve the process and enrich process understanding. Consequently, QbD should be viewed not as a development-stage exercise but as a lifecycle strategy for maintaining robust tablet manufacturing.

V. CONCLUSION

Quality by Design provides a systematic framework for developing oral tablet manufacturing processes based on scientific understanding, risk management, experimentation, and proactive control of variability. The approach begins with definition of the QTPP and identification of CQAs and then proceeds toward evaluation of material attributes and process parameters. This provides a structured pathway for understanding how formulation and manufacturing variables influence final product quality. ICH Q8 specifically supports this enhanced approach through systematic evaluation of formulation and manufacturing

processes and establishment of an appropriate control strategy.

The identification and optimization of CPPs are central to achieving consistent tablet quality. Risk assessment can prioritize potentially influential variables, while DoE can quantify their effects and interactions. Rather than focusing exclusively on individual parameter settings, QbD encourages development of multidimensional process understanding and, where justified, establishment of a design space. Such knowledge can help manufacturers balance multiple CQAs, including hardness, friability, disintegration, dissolution, assay, and content uniformity.

An effective control strategy converts this knowledge into routine manufacturing controls. Process validation and continued process verification then provide mechanisms for demonstrating and maintaining a state of control. FDA guidance emphasizes a lifecycle approach to process validation, while ICH materials recognize continuous monitoring as an important means of evaluating process performance. These principles reduce reliance on end-product testing alone and encourage prevention and early detection of quality problems.

Overall, QbD-based tablet development can improve process robustness, facilitate scale-up and technology transfer, and provide a stronger scientific basis for lifecycle management. Its success depends on meaningful process understanding rather than simply generating documentation or conducting statistical experiments. Future development can increasingly integrate real-time monitoring, multivariate analysis, process analytical technologies, and advanced manufacturing systems. When appropriately implemented within the pharmaceutical quality system, QbD provides a comprehensive foundation for producing oral tablets with consistent quality and performance.

REFERENCES

1. Aksu, B., Paradkar, A., de Matas, M., Özer, Ö., Güneri, T., & York, P. (2013). A quality by design approach using artificial intelligence techniques to control the critical quality attributes of ramipril tablets manufactured by wet granulation. *Pharmaceutical Development and Technology*, 18(1), 236–245. <https://doi.org/10.3109/10837450.2012.705294>
2. Charoo, N. A., Shamsher, A. A. A., Zidan, A. S., & Rahman, Z. (2012). Quality by design approach for formulation development: A case study of dispersible tablets.

International Journal of Pharmaceutics, 423(2), 167–178.
<https://doi.org/10.1016/j.ijpharm.2011.12.024>

3. Chávez, P.-F., Lebrun, P., Sacré, P.-Y., De Bleye, C., Netchacovitch, L., Cuypers, S., Mantanus, J., Motte, H., Schubert, M., Evrard, B., Hubert, P., & Ziemons, E. (2015). Optimization of a pharmaceutical tablet formulation based on a design space approach and using vibrational spectroscopy as PAT tool. *International Journal of Pharmaceutics*, 486(1–2), 13–20. <https://doi.org/10.1016/j.ijpharm.2015.03.025>
4. Djuris, J., Medarevic, D., Krstic, M., Djuric, Z., & Ibric, S. (2013). Application of quality by design concepts in the development of fluidized bed granulation and tableting processes. *Journal of Pharmaceutical Sciences*, 102(6), 1869–1882. <https://doi.org/10.1002/jps.23530>
5. Grangeia, H. B., Silva, C., Simões, S. P., & Reis, M. S. (2020). Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. *European Journal of Pharmaceutics and Biopharmaceutics*, 147, 19–37. <https://doi.org/10.1016/j.ejpb.2019.12.007>
6. Ko, S. J., Lee, J.-H., Kang, C.-Y., & Park, J.-B. (2018). Granulation development in batch-to-batch and continuous processes from a quality by design perspective. *Journal of Drug Delivery Science and Technology*, 46, 34–45. <https://doi.org/10.1016/j.jddst.2018.04.012>
7. Kushner, J., Langdon, B. A., Hicks, I., Song, D., Li, F., Kathiria, L., Kane, A., Ranade, G., & Agarwal, K. (2014). A quality-by-design study for an immediate-release tablet platform: Examining the relative impact of active pharmaceutical ingredient properties, processing methods, and excipient variability on drug product quality attributes. *Journal of Pharmaceutical Sciences*, 103(2), 527–538. <https://doi.org/10.1002/jps.23810>
8. Won, D. H., Park, H., Ha, E.-S., Kim, H.-H., Jang, S. W., & Kim, M.-S. (2021). Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on quality by design (QbD). *International Journal of Pharmaceutics*, 605, 120838. <https://doi.org/10.1016/j.ijpharm.2021.120838>

9. Yekpe, K., & Abatzoglou, N. (2018). Developing a quality by design approach to model tablet dissolution testing: An industrial case study. *Pharmaceutical Development and Technology*, 23(6), 1–9. <https://doi.org/10.1080/10837450.2017.1392566>
10. Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. *AAPS Journal*, 16(4), 771–783. <https://doi.org/10.1208/s12248-014-9598-3>
11. Yu, L. X. (2008). Pharmaceutical quality by design: Product and process development, understanding, and control. *Pharmaceutical Research*, 25, 781–791.